logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Public Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Biotechnology
Filter

Biotechnology

Categories

Sectors

Locations

Exchange

Diversified Pipeline of Critical Care Products | Citius Pharmaceuticals

Dec 8, 2023

Life Science

The 7th CBIIC Brings Infinite Business Opportunities

Apr 3, 2023

Life Science

Healthcare and Life Sciences in North America: Opportunities & Post-Pandemic Outlook

Dec 12, 2022

Life Science

细胞与基因疗法

H1 2022 Healthcare and Life Sciences Worldwide: Cell and Gene Therapy (CGT)

Dec 6, 2022

Life Science

H1 2022 Healthcare and Life Sciences in North America: Market Insights

Nov 29, 2022

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel Terminates License Agreement with Shiseido

Dec 21, 2021

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel Closed Final Tranche of Strategic Investment Commitment

Dec 21, 2021

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing

Nov 11, 2021

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team

Nov 9, 2021

Life Science

Hemostemix PR

Hemostemix Confirms OTCQB Listing

Oct 28, 2021

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line

Oct 28, 2021

Life Science

RepliCel Announces Dermal Injector Update

Oct 27, 2021

Life Science

headway-F2KRf_QfCqw-unsplash

Looking for your next +30% opportunity? Join our multi-sector high growth stock virtual event

Oct 27, 2021

Cannabis, Consumer Goods, Life Science, Technology

Hemostemix PR

Hemostemix Confirms OTCQB Application is Filed

Oct 19, 2021

Cannabis, Consumer Goods, Life Science, Technology

RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy

Oct 18, 2021

Cannabis, Consumer Goods, Life Science, Technology

Hemostemix PR

Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer

Oct 14, 2021

Cannabis, Consumer Goods, Life Science, Technology

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor

Oct 12, 2021

Cannabis, Consumer Goods, Life Science, Technology

Hemostemix PR

Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to No Chest Pain

Oct 4, 2021

Cannabis, Consumer Goods, Life Science, Technology

  • 1
  • 2
  • 3
  • 4
  • 5
  • Next ››

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2025 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada